Myriad Genetics, Inc. (MYGN) Tops Q4 EPS by 1c; Guides FY12
Tweet
Share
E-mailGet Alerts MYGN Hot Sheet
Price: $4.50 --0%
Revenue Growth %: -2.7%
Financial Fact:
Total revenue: 177.5M
Today's EPS Names:
JFIN, KEQU, LASE, More
Revenue Growth %: -2.7%
Financial Fact:
Total revenue: 177.5M
Today's EPS Names:
JFIN, KEQU, LASE, More
Join SI Premium – FREE
Myriad Genetics, Inc. (NASDAQ: MYGN) reported Q4 EPS of $0.30, $0.01 better than the analyst estimate of $0.29. Revenue for the quarter came in at $107.4 million versus the consensus estimate of $104.43 million.
Myriad Genetics, Inc. sees FY2012 EPS of $1.20-$1.25, versus the consensus of $1.25. Myriad Genetics, Inc. sees FY2012 revenue of $445-$465 million, versus the consensus of $450.8 million.
Myriad Genetics, Inc. sees FY2012 EPS of $1.20-$1.25, versus the consensus of $1.25. Myriad Genetics, Inc. sees FY2012 revenue of $445-$465 million, versus the consensus of $450.8 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Kroger (KR) Reports In-Line Q1 EPS, Beats on Revenue; Offers FY27 EPS Guidance
- Smith & Wesson Brands (SWBI) Tops Q4 EPS by 15c
- Steel Dynamics issues Q2 2026 earnings guidance of $3.51-$3.55 per share
Create E-mail Alert Related Categories
Earnings, GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
